English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Bayer Builds China Diabetes Portfolio with SciLin Launch

Sep. 2, 2010

On September 3, 2010, Bayer Schering Pharma launched SciLin, the recombinant insulin whose China-marketing rights it bought from Polish Bioton in 2009. Bayer had paid $43.5 million for 15 years of SciLin’s China rights. At the time of the agreement, Bayer forecasted that SciLin should generate between $1.5-2 billion of revenues in China during the term of the agreement.